



## **Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference**

May 24, 2011

PARSIPPANY, N.J., May 24, 2011 /PRNewswire via COMTEX/ --

[Pacira Pharmaceuticals, Inc.](#) (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that Gary Patou, M.D., chief medical officer, is scheduled to present at the UBS Global Specialty Pharmaceuticals Conference being held in London on Wednesday, May 25, 2011 at noon BST. Dr. Patou is expected to present an overview of the company.

A live audio webcast of Pacira's presentation can be accessed by visiting the investors section of the company's website at [investor.pacira.com](http://investor.pacira.com). A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.

### **About Pacira**

Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postoperative analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at [www.pacira.com](http://www.pacira.com).

### **Contacts:**

James S. Scibetta  
Chief Financial Officer  
Pacira Pharmaceuticals, Inc.  
(973) 254-3570

Jennifer Beugelmans  
Vice President, Investor Relations  
Pure Communications, Inc.  
(646) 596-7473

SOURCE Pacira Pharmaceuticals, Inc.